The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2017 | PD-L1 agents in the treatment of NSCLC
David Gandara, MD, from the University of California, Davis, CA discusses the results of the OAK trial (NCT02008227) and how they impact the treatment landscape of advanced stage, non-small cell lung cancer (NSCLC). This is the first phase III trial to investigate the safety and efficacy of the anti-PD-L1 agent, atezolizumab, compared to docetaxel, in patients with NSCLC. The results indicated that there were better patient outcomes when the received atezolizumab, and this was also associated with high expression of PD-L1. Interestingly, even patients with no expression of PD-L1, showed some clinical benefit. This interview was recorded at the annual meeting of the European Lung Cancer Conference (ELCC) 2017, Geneva, Switzerland.
